Request for Expressions of Interest: Exploratory Clinical Trials of Non-insulin Adjunct Therapies in Type 1 Diabetes
Request for Expressions of Interest: Exploratory Clinical Trials of Non-insulin Adjunct Therapies in Type 1 Diabetes Expression of Interest Deadline: July 11, 2014 JDRF, the world’s leading non-profit organization with the mission to cure, treat and prevent type 1 diabetes (T1D), invites Expressions of Interest (EOI) for clinical trials to evaluate non-insulin based adjunct therapies for improved glycemic and overall metabolic control of T1D. JDRF has an unprecedented opportunity to make progress in the clinical assessment of adjunctive therapies for T1D that move beyond an insulin-centric view of the disease. At present, several agents–mostly approved T2D therapies such as incretins, SGLT inhibitors, metformin– are under clinical investigation to assess the benefit: risk profile in T1D. However, a systematic clinical phenotyping of the heterogeneous disease to enable personalized interventions addressing specific dysfunctional pathways or an understanding of the mechanistic pathology is yet to be undertaken. It is our goal to de-convolute the T1D disease complexity such that sub-groups of individuals can be identified and stratified to determine optimal therapeutic regimen of non-insulin adjunct therapies, thus maximizing the benefit: risk ratio for the patients. JDRF wishes to solicit expressions of interest for clinical trials in established from academic and industry applicants T1D to test the safety, efficacy, and potential syner...
Source: ScanGrants feed - Category: Research Authors: JDRF Source Type: funding
More News: Academia | Clinical Trials | Diabetes | Diabetes Type 1 | Endocrinology | Fortamet | Insulin | Metformin | Pathology | PET Scan | Research